JP2011513315A5 - - Google Patents

Download PDF

Info

Publication number
JP2011513315A5
JP2011513315A5 JP2010548807A JP2010548807A JP2011513315A5 JP 2011513315 A5 JP2011513315 A5 JP 2011513315A5 JP 2010548807 A JP2010548807 A JP 2010548807A JP 2010548807 A JP2010548807 A JP 2010548807A JP 2011513315 A5 JP2011513315 A5 JP 2011513315A5
Authority
JP
Japan
Prior art keywords
antimetabolite
pharmaceutical composition
use according
administered
rukanton
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010548807A
Other languages
English (en)
Japanese (ja)
Other versions
JP5590560B2 (ja
JP2011513315A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/034629 external-priority patent/WO2009108573A1/en
Publication of JP2011513315A publication Critical patent/JP2011513315A/ja
Publication of JP2011513315A5 publication Critical patent/JP2011513315A5/ja
Application granted granted Critical
Publication of JP5590560B2 publication Critical patent/JP5590560B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010548807A 2008-02-29 2009-02-20 組合せ抗がん剤 Expired - Fee Related JP5590560B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3283108P 2008-02-29 2008-02-29
US61/032,831 2008-02-29
PCT/US2009/034629 WO2009108573A1 (en) 2008-02-29 2009-02-20 Combination anti-cancer agents

Publications (3)

Publication Number Publication Date
JP2011513315A JP2011513315A (ja) 2011-04-28
JP2011513315A5 true JP2011513315A5 (enExample) 2012-04-05
JP5590560B2 JP5590560B2 (ja) 2014-09-17

Family

ID=40566524

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010548807A Expired - Fee Related JP5590560B2 (ja) 2008-02-29 2009-02-20 組合せ抗がん剤

Country Status (13)

Country Link
US (1) US20090221615A1 (enExample)
EP (1) EP2257285A1 (enExample)
JP (1) JP5590560B2 (enExample)
KR (1) KR20100126453A (enExample)
CN (1) CN102014895A (enExample)
AU (1) AU2009219464B2 (enExample)
BR (1) BRPI0908398A2 (enExample)
CA (1) CA2717100A1 (enExample)
IL (1) IL207859A (enExample)
MX (1) MX2010009502A (enExample)
RU (1) RU2516027C2 (enExample)
WO (1) WO2009108573A1 (enExample)
ZA (1) ZA201006123B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6182313B2 (ja) * 2010-03-08 2017-08-16 スペクトラム ファーマシューティカルズ インコーポレイテッド 癌治療のためのチオキサントンをベースとしたオートファジー阻害剤療法
EP2425830A1 (en) 2010-09-03 2012-03-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synergistic drug combination for the treatment of cancer
WO2023114245A2 (en) * 2021-12-14 2023-06-22 Radin Daniel Pierce Compositions and methods for treating cancers of the central nervous system (cns), including glioblastoma and chemoresistant cns tumors, and related compositions and methods for inhibiting and eliminating cns cancer stem cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ504108A (en) * 1997-09-26 2002-06-28 Noven Pharma Bioadhesive compositions comprising a polyvinylpyrrolidone polymer and methods for topical administration of active agents
US6391911B1 (en) * 1999-02-26 2002-05-21 Robert E. Bases Coadministration of lucanthone and radiation for treatment of cancer
EP1971338B8 (en) * 2005-12-22 2011-09-21 AstraZeneca AB Combination of zd6474 and pemetrexed
JP2009520787A (ja) * 2005-12-22 2009-05-28 アストラゼネカ アクチボラグ Azd2171およびペメトレキセドの組み合わせ

Similar Documents

Publication Publication Date Title
JP2014532704A5 (enExample)
JP2012082215A5 (enExample)
ES2916649T1 (es) Composiciones y usos para el tratamiento de la esclerosis múltiple
JP2010501575A5 (enExample)
JP2011068653A5 (enExample)
JP2009525343A5 (enExample)
RU2010133489A (ru) Применение ингибиторов гамма-секретазы для лечения рака
JP2012180381A5 (enExample)
PH12015502134A1 (en) Mosapride sustained-release preparation for providing pharmacological and clinical effects with once-a-day administration
JP2013209384A5 (enExample)
JP2010525050A5 (enExample)
JP2012193216A5 (enExample)
JP2014040437A5 (enExample)
FI3626270T3 (fi) Sydän- ja verisuonitautien hoito
ME02474B (me) Terapijski režimi
JP2010526837A5 (enExample)
JP2013516493A5 (enExample)
JP2013541583A5 (enExample)
JP2011513315A5 (enExample)
JP2016505050A5 (enExample)
RU2012108144A (ru) Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами
JP2014510780A5 (enExample)
IL300144A (en) Benzazepines are combined for the treatment of Tourette syndrome
RU2010139840A (ru) Комбинация противораковых агентов
JP2012041314A5 (enExample)